GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pardes Biosciences Inc (NAS:PRDS) » Definitions » Price-to-Free-Cash-Flow

Pardes Biosciences (Pardes Biosciences) Price-to-Free-Cash-Flow : N/A (As of May. 27, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pardes Biosciences Price-to-Free-Cash-Flow?

As of today (2024-05-27), Pardes Biosciences's share price is $2.16. Pardes Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.33. Hence, Pardes Biosciences's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Pardes Biosciences's Price-to-Free-Cash-Flow or its related term are showing as below:

PRDS's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.53
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Pardes Biosciences's Free Cash Flow per Share for the three months ended in Jun. 2023 was $-0.33. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.33.


Pardes Biosciences Price-to-Free-Cash-Flow Historical Data

The historical data trend for Pardes Biosciences's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pardes Biosciences Price-to-Free-Cash-Flow Chart

Pardes Biosciences Annual Data
Trend Dec20 Dec21 Dec22
Price-to-Free-Cash-Flow
- - -

Pardes Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pardes Biosciences's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Pardes Biosciences's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pardes Biosciences's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pardes Biosciences's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Pardes Biosciences's Price-to-Free-Cash-Flow falls into.



Pardes Biosciences Price-to-Free-Cash-Flow Calculation

Pardes Biosciences's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.16/-1.325
=N/A

Pardes Biosciences's Share Price of today is $2.16.
Pardes Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.33.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Pardes Biosciences  (NAS:PRDS) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Pardes Biosciences Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Pardes Biosciences's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Pardes Biosciences (Pardes Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
2173 Salk Avenue, Suite 250, PMB No. 052, Carlsbad, CA, USA, 92008
Pardes Biosciences Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel oral-antiviral therapeutics to improve the lives of patients suffering from life-threatening disease, starting with the lead product candidate, pomotrelvir (formerly known as PBI-0451), which is in clinical development and intended to treat COVID-19 in adult and pediatric patients. COVID-19 is caused by infection with the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Pomotrelvir inhibits the main coronaviral cysteine protease, a viral protein essential for the replication of all known coronaviruses, including SARS-CoV-2.
Executives
Fs Development Holdings Ii, Llc 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Opportunity Fund V, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Fund V, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Sean P. Brusky officer: Chief Commercial Officer C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Thomas G Wiggans director, officer: Chief Executive Officer
Foresite Capital Management V, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Pottage John C Jr director ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Alsup Laurie Smaldone director 190 WOOSAMONSA RD, PENNINGTON NJ 08534
Heidi Henson officer: Chief Financial Officer 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
J Jay Lobell director 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Brian Philippe Tinmouth officer: Chief Business & Strategy Ofcr 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Brian Kearney officer: Chief Development Officer C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Lee D Arnold officer: Chief Scientific Officer C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013
Uri A Lopatin director, officer: President and CEO C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013